Gesynta Pharma’s lead compound, vipoglanstat, is a groundbreaking treatment for endometriosis, a debilitating chronic inflammatory disease affecting over 10% of women of reproductive age.
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, forming lesions that cause severe and debilitating chronic pelvic pain. Despite its prevalence, current treatment options are inadequate. Hormonal contraceptives are commonly used but are unsuitable for women trying to conceive and may not effectively manage symptoms. More aggressive hormonal therapies, such as GnRH analogs, come with significant side effects, including hot flashes, mood disturbances, and bone density loss, making them unsuitable for long-term use. Surgical interventions are invasive, often require repeat procedures, and, in severe cases, may necessitate the removal of the uterus or ovaries.
Vipoglanstat represents a novel approach as a non-hormonal, non-opioid, disease-modifying therapy. By targeting mPGES-1, an enzyme linked to pain and disease progression, vipoglanstat has demonstrated a favorable safety profile and beneficial pharmacological properties in Phase I and II clinical trials. Preclinical proof-of-concept studies in advanced disease models have shown significant reductions in endometrial lesions, improvements in pain, and enhancements in overall well-being. A Phase II clinical trial for endometriosis patients is set to begin in 2025.
Founded by a team of PhDs and life science executives - including Patric Stenberg PhD, Charlotte Edenius M.D., PhD, Ralf Morgenstern, PhD, Gunilla Ekström, MD, PhD and Urban Paulsson, LLM - who have over 100 years of combined experience in the life sciences industry across all phases of drug development, Gesynta Pharma is poised to be a breakthrough in the frontier of endometriosis care.
Amboy Street is excited to support Gesynta Pharma alongside Hadean Ventures, Industrifonden, Linc, Foreground Capital, Catalyze Capital and Stephen Industries.
“This SEK 304 million funding round marks a pivotal milestone for Gesynta Pharma, demonstrating strong international investor confidence in our approach to treating endometriosis. With these funds, we will advance vipoglanstat towards being Phase III-ready, aiming to provide patients with a disease-modifying treatment option that overcomes the efficacy and tolerability limitations of current therapies,” said Patric Stenberg, CEO of Gesynta Pharma.
Carli Sapir of Amboy Street Ventures is excited for what the future holds for Gesynta Pharma.
“We are thrilled to support Gesynta Pharma as they develop a better solution for those suffering from endometriosis. Their innovative, non-hormonal approach has the potential to transform care and improve the lives of millions of women worldwide.”
Gesynta Pharma is one of ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading tele-health abortion provider, Contraline, the maker of male birth control and Granata Bio, a biopharma platform developing and commercializing IVF medication. See the full portfolio here. To learn more about Gesynta Pharma visit https://www.gesynta.se/.
